Assessing funding for AMR research in South Korea

The Research Investments in Global Health (ResIn) study were delighted to collaborate with public health researchers in South Korea (Republic of Korea) on an analysis of R&D funding related to antimicrobial resistance (AMR).

Our original article has been published in the Journal of Global Antimicrobial Resistance. We assessed 198 project reports that had a total funding of US$18.3 million. Much of the funding (61.5%) was for implementation and operational research, and universities were the lead institutions for 73.2% of the awards. There was little funding for projects that had a focus on global health, and few projects had a focus on specific pathogens.

Suggested citation –  Ryu SH, Head MG, Kim BI, Hwang JC, Cho EH. Are we investing wisely? A systematic analysis of nationally funded antimicrobial resistance projects in Korea, 2003-2013. Journal of Global Antimicrobial Resistance. 2016. doi:10.1016/j.jgar.2016.03.007

ResIn is offering bursaries for two summer students in 2016!

The Research Investments in Global Health study (ResIn) is delighted to have won a small grant from the Royal Society for Tropical Medicine and Hygiene! This will allow us to host two students this summer on paid bursaries at the University of Southampton, to pilot methods that combine research investment analyses with geospatial techniques. These placements would suit medical, MSc/Bsc, nursing students etc (all scientific disciplines considered, recent graduates or more experienced colleagues between posts will also be considered). For the geospatial activity, experience in GIS, geography and/or associated disciplines will be required.

More information…

We have available two (non-laboratory) research placements at the university this summer, one based at Southampton General Hospital in the Faculty of Medicine, and one (most likely) located at the university Highfield campus. The bursaries will each be £1600 for 10 weeks (pro-rata payment for shorter placement will be considered). Timing is flexible across July to October.

Project title – Combining research investments analyses and malaria maps in Africa – are we investing limited resources wisely? Part of the Research Investments in Global Health study, ResIn, www.researchinvestments.org

People involved – Michael Head (project lead, main supervisor), Stuart Clarke, Becky Brown (Faculty of Medicine, Southampton), Andy Tatem (Geography, Southampton), Joseph Fitchett (Harvard)

Background – The study is analysing global trends in funding for infectious disease research. We are currently collating research funding data from all the nations in the G20 and analysing the individual awards for relevance to infection, and then categorising them under diseases and disease areas, pathogens and type of science. In 12-18 months’ time we will have finalised a large global dataset of funding trends over the last 15 years and be able to identify areas of national and international research strength, areas of funding neglect, and be able to inform the R&D agenda of how to distribute limited financial resources as equitably as possible.

See http://www.sciencedirect.com/science/article/pii/S2352396415302449  for our latest paper on mapping the UK funding landscape, and http://researchinvestments.org/publications/ for the rest of our publications to give an idea of the sort of work we produce.

Placement activity of student handling the research funding data –  Here, we are going to focus on research investment data from the world’s leading global health funders. Some of this is already extracted and categorised, some of which the research funding student will need to collate and categorise (full supervision and support provided here, of course). As well as disease categories, they will need to pick out the awards with a geographical focus in sub-Saharan Africa e.g. ‘malaria vaccines trial in Kenya’. They will need to find out as precisely as possible where that research was taking place (reading study abstract, googling, institutional websites, reading published outputs related to the study etc), so it can be mapped by the geography student. There will be plenty of playing around in spreadsheets, with excel equations and manual sifting, analysis within Stata, and generating results via tables and visualisations, in order to generate some results about the extent and nature of the selected studies.

The geography/geospatial student – Having received a dataset of selected studies related to malaria that have a specified geographical focus, they will then integrate this information with existing datasets. The Malaria Atlas Project, http://www.map.ox.ac.uk/, has mapped malaria burden to every grid square in sub-Saharan Africa.  The WorldPop data is also openly available, http://www.worldpop.org.uk/. Using GIS/other methods, the student will produce some visualisations describing the location of where the research funding is targeted – what are the burdens, demographics and geography of these areas? This can help to answer questions such as – Are investments biased towards high transmission, sparsely populated rural areas, or high-density elimination settings? Are there geographic regions that have been neglected but could greatly benefit from being the focus of investment? Are we investing as equitably and ethically as possible?

Placement outputs
– written data and visuals;
– at least one peer-reviewed publication (on which both students would be authors);
– there is a small budget for conference attendance to present the results;
– also plans to host a meeting in London (probably at the Wellcome Trust) at the end of the project to highlight the study and results to influential funders and policymakers with an interest in this area, this is a good chance to build useful links, travel to and from London would be paid for.

Skills required – for the research investments student – a systematic approach to working with plenty of attention to detail, experience handling data in excel and any other stats/epidemiological software would be useful but not essential, interests in global health and infectious diseases (malaria in particular)
– for the geography/geospatial student – knowledge of GIS, experience with geospatial techniques, interests in global health and infectious diseases (malaria in particular)

If interested – send your CV and brief email of your background/interests in these areas to Michael Head at the University of Southampton, m.head@soton.ac.uk . Please state which of the two placements you are interested in. Deadline for expressions of interest – 31 May 2016.

New update paper – 17 year of funding trends and new global health burden metrics

The ResIn study has published a new paper that covers all 17 years of the UK dataset so far (1997-2013) and compiled some new metrics describing the comparisons between disease burden and amount of research funding going towards specific infectious diseases. We find, for example, that some of the neglected tropical diseases continue to be well-funded and could probably be described as a UK research strength; influenza also comes out well in our analysis thanks to relatively recent large investments in respiratory research. Conversely, there is still little funding available for some non-HIV sexually-transmitted infections such as gonorrhoea and syphilis.

The full paper is open access, published in EBioMedicine. Click here for the manuscript.

Citation –
Head MG, Fitchett JR, Nageshwaran V, Kumari N, Hayward AC, Atun R. Research investments in global health: a systematic analysis of UK infectious disease research funding and global health metrics, 1997-2013. EBioMedicine. 2015. doi:10.1016/j.ebiom.2015.12.016

ResIn contributes to WHO R&D Observatory call for evidence

We have had our latest manuscript published in the journal Health Research Policy and Systems. This paper is the first to be published as part of the World Health Organisation R&D Observatory call for evidence.

Our article compares research investment to United Kingdom institutions with published outputs for tuberculosis, HIV and malaria. We analyse these by numbers of publications and citations and by disease and type of science, in order to identify what research is most prolific in terms of published outputs in these three disease areas.

To see our findings, click here for the full-open access paper.

And click here to see more about the R&D Observatory call for evidence

Neonatal infectious disease commentary in Lancet Global Health

ResIn contributed data and investigator time to a commentary that appeared in Lancet Global Health, entitled Neonatal infection: a major burden with minimal funding. There are around 0.7 million neonatal deaths worldwide each year due to infectious diseases, but when correlating investment against disease burden for 25 infections, neonatal disease ranks lowest of all. The commentary covers more on that point, plus some pragmatic discussion around the need for capacity-strengthening and raising of awareness in this important area.

See the link above for the full commentary, also see our publications page for the rest of our published outputs.

 

Two papers published by ResIn study – pneumonia and STIs

Two papers published by Research Investments in Global Health (ResIn) study – pneumonia and STIs 

The ResIn study has published a couple of papers over the summer of 2015, covering research funding for pneumonia (published in EBioMedicine), and also sexually-transmitted infections (published in the Journal of Global Health). Both papers are open-access.

Click here for the pneumonia paper.

Click here for the STIs paper.

 

ResIn is recruiting!

The Research Investments in Global Health study is recruiting!

Research Fellow in infectious disease research investment analyses
Location:  Southampton General Hospital
Salary:   £28,695 to £35,256
Full Time Fixed Term
Closing Date:   Friday 28 August 2015

 

We wish to appoint a (non-laboratory) Research Fellow in infectious disease research investment analyses. The ResIn team (as of October 2015) will be led by Dr Stuart Clarke and based within the University of Southampton at Southampton General Hospital. The project has been awarded funding from the Bill & Melinda Gates Foundation to collate funding data from the G20 countries relating to infectious diseases (in particular pneumonia and neonatal infection research) and to assess how much funding is awarded to each disease area, how well investment correlates with the burden of disease and to measure the impact and outputs of research.

This post provides an exciting opportunity for someone with an interest in infectious disease research. It will also be of interest to those who would enjoy building tools and analyses that will be useful in informing the decisions and priority-setting of high-ranking policymakers (e.g. the World Health Organisation), the world’s leading biomedical and health research funders, and individual research institutions, groups and societies and researchers.

Applications are invited from those with an interest in infectious diseases, health policy or disease burden measurement. Relevant experience of a systematic and detailed approach to carrying out research projects is essential.

Click here for more information and to apply.

 

ResIn receives funding from the Bill & Melinda Gates Foundation!

We are delighted to announce that the Research Investments in Global Health study has received funding from the Bill & Melinda Gates Foundation for a two year study. The award is for $586k (approximately £378k) and will expand on the UK analyses, and investigate infectious disease research investments (in particular pneumonia, and maternal & neonatal infections) across the G20 countries. We will continue to assess investment against metrics of the global and national burdens of disease, and we will also measure research outputs and the impact of research. The study will be based at the University of Southampton and led by Dr Stuart Clarke.

Pneumonia and maternal and neonatal infectious diseases (such as influenza, tetanus and respiratory syncytial virus) have been cited as priority areas by both the World Health Organisation (WHO) and the Gates Foundation. The 2013 Global Burden of Disease study estimated there to be 800,000 pneumonia deaths annually worldwide and the disease continues to be the number one infectious killer of children under the age of five, with more deaths than HIV, TB and malaria combined. This is despite the existence of lifesaving treatments and prevention measures, such as effective vaccines.

“The high disease burden, particularly amongst young and elderly populations in poor to middle income countries, could potentially be addressed by further investment in research,” says Dr Stuart Clarke from the University of Southampton’s Faculty of Medicine, who is leading the study.

“We will quantify the contribution of research funds that these infections receive compared to research involving other pathogens that are important in human health. This will give policy makers a comprehensive picture of where there’s been a lack of funding relative to the impact of the disease and help to set global research investment priorities,” Dr Clarke adds.

Based within the University’s Faculty of Medicine, the study also contributes to the Global Health Research Institute, headed by co-applicant Professor Marie-Louise Newell (also of Southampton). The findings will be compiled in an open-access database, creating a wealth of information for all funders, policymakers and researchers to view and apply to their own work.

Co-applicant and senior research fellow, Michael Head explains: “The database will allow funders to identify existing research in areas of mutual interest, help researchers identify collaborators, expertise and infrastructure, and support high-level policymakers (such as the WHO R&D Observatory) to identify funding trends and the relative value of investments in their areas of interest.”

The two year study will start in October 2015.

‘Funding for infectious disease institutions’ paper published in JRSM Open

The latest publication to come out of the Research Investments in Global Health study is published today in JRSM Open. It covers the institutions that receive the funding and shows how for some disease areas, there are clear centres of excellence and some clear gaps in their portfolios.

The abstract is below, and see the full open access paper at the JRSM Open website.


Systematic analysis of funding awarded to inst
itutions in the United Kingdom for infectious disease research, 1997–2010

Objectives This study aimed to assess the research investments made to UK institutions for all infectious disease research and identify the direction of spend by institution.

Design Systematic analysis. Databases and websites were systematically searched for information on relevant studies funded for the period 1997–2010.

Setting UK institutions carrying out infectious disease research.

Participants None.

Main outcome measures Twenty academic institutions receiving greatest sum investments across infection are included here, also NHS sites, Sanger Institute, Health Protection Agency and the Medical Research Council. We measured total funding, median award size, disease areas and position of research along the R&D value chain.

Results Included institutions accounted for £2.1 billion across 5003 studies. Imperial College and University of Oxford received the most investment. Imperial College led the most studies. The Liverpool and London Schools of Tropical Medicine had highest median award size, whereas the NHS sites combined had many smaller studies. Sum NHS funding appears to be declining over time, whilst university income is relatively stable. Several institutions concentrate almost exclusively on pre-clinical research. In some areas, there is clearly a leading institution, e.g. Aberdeen and mycology research or UCL and antimicrobial resistance.

Conclusion UK institutions carry out research across a wide range of infectious disease areas. This analysis can identify centres of excellence and help inform future resource allocation for research priorities. Institutions can use this analysis for establishing expertise within their groups, identifying external collaborators and informing local research strategy.

Watch video of ResIn data presented at BSAC meeting

ResIn co-founder Michael Head recently presented data on antimicrobial resistance research funding at a British Society for Antimicrobial Chemotherapy meeting, taking place at the Wellcome Collection in London.

To see what Michael had to say, Click here to visit the website showing the talks presented at the meeting entitled ‘Re-stoking the therapy pipeline – How to stimulate the development of new antibiotics, diagnostics and novel therapies’.